Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease-a prospective pilot study.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
03
05
2024
accepted:
09
10
2024
revised:
23
08
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
20
10
2024
Statut:
aheadofprint
Résumé
Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED. A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit. Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1). Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.
METHODS
METHODS
A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.
RESULTS
RESULTS
Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).
CONCLUSIONS
CONCLUSIONS
Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery.
Identifiants
pubmed: 39428445
doi: 10.1038/s41433-024-03403-8
pii: 10.1038/s41433-024-03403-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Jain AP, Jaru-Ampornpan P, Douglas RS. Thyroid eye disease: redefining its management—a review. Clin Exp Ophthalmol. 2021;49:203–11.
doi: 10.1111/ceo.13899
pubmed: 33484076
Lee DC, Young SM, Kim YD, Woo KI. Course of upper eyelid retraction in thyroid eye disease. Br J Ophthalmol. 2020;104:254–9.
doi: 10.1136/bjophthalmol-2018-313578
pubmed: 31079052
Dutton JJ. Anatomic considerations in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34:S7–12.
doi: 10.1097/IOP.0000000000001122
pubmed: 29870437
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43–67.
doi: 10.1530/EJE-21-0479
pubmed: 34297684
Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9:181.
pubmed: 18231614
pmcid: 2213889
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016;48:134.
doi: 10.4103/0253-7613.178825
pubmed: 27127315
pmcid: 4825428
Kaplan SA, Chughtai BI. Safety of tamsulosin: a systematic review of randomized trials with a focus on women and children. Drug Saf. 2018;41:835–42.
doi: 10.1007/s40264-018-0674-y
pubmed: 29737501
Leshno A, Smadar L, Kapelushnik N, Serlin T, Prat D, Priel A, et al. New insight into the physiologic function of Müller’s muscle. Exp Eye Res. 2021;202:108336.
Rüfer F, Schröder A, Erb C. White-to-white corneal diameter: normal values in healthy humans obtained with the Orbscan II topography system. Cornea 2005;24:259–61.
doi: 10.1097/01.ico.0000148312.01805.53
pubmed: 15778595
Putterman AM. Margin reflex distance (MRD) 1, 2, and 3. Ophthalmic Plast Reconstr Surg. 2012;28:308–11.
doi: 10.1097/IOP.0b013e3182523b7f
pubmed: 22785597
Wiersinga WM. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:359–70.
doi: 10.1016/j.beem.2011.11.001
pubmed: 22632371
Simmons BA, Tran C, Pham CM, Shriver EM. The effect of teprotumumab on eyelid position in patients with thyroid eye disease. Plast Reconstr Surg Glob Open. 2022;10:E4287.
doi: 10.1097/GOX.0000000000004287
pubmed: 35475287
pmcid: 9029877
Morgenstern KE, Evanchan J, Foster JA, Cahill KV, Burns JA, Holck DE, et al. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthalmic Plast Reconstr Surg. 2004;20:181–5.
doi: 10.1097/00002341-200405000-00001
pubmed: 15167723
Mancini R, Khadavi NM, Goldberg RA. Nonsurgical management of upper eyelid margin asymmetry using hyaluronic acid gel filler. Ophthalmic Plast Reconstr Surg. 2011;27:1–3.
doi: 10.1097/IOP.0b013e3181c2a16d
pubmed: 20551854
Osaki T, Monteiro L, Osaki M. Management of eyelid retraction related to thyroid eye disease. Taiwan J Ophthalmol. 2022;12:12.
doi: 10.4103/tjo.tjo_57_21
pubmed: 35399960
pmcid: 8988987
Young SM, Kim YD, Lang SS, Woo KI. Transconjunctival triamcinolone injection for upper lid retraction in thyroid eye disease-a new injection method. Ophthalmic Plast Reconstr Surg. 2018;34:587–93.
doi: 10.1097/IOP.0000000000001120
pubmed: 29672347
Xu D, Liu Y, Xu H, Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol. 2012;47:34–41.
doi: 10.1016/j.jcjo.2011.12.005
pubmed: 22333849